Summary of funding initiatives (Simpkin et al.) + E9(R1) Statistical methods update (FDA)

Dear All: Two updates today.

First, our colleagues at London School of Economics have just published a review of antibiotic innovation incentives that includes a detailed review of some of the currently available sources of funding (Simpkin VL et al., Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J Antibiot, 1 Nov 2017).

As the authors noted in a prior paper, there have been more than 50 initiatives in the past decade on this topic! To keep things manageable, this new paper limits itself to initiatives at the multi-lateral, EU, US, and UK levels. This figure from (their Figure 4) gives you a quick sense on the activities they have surveyed:

Picture

​The paper is open access and I encourage you to take a look if you want to be sure you have considered all the sources of funding that might be relevant to your work.

Second, FDA has announced the availability of a draft guidance entitled ‘‘E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials.’’ Here is the PDF of the announcement and here is link to the draft guidance. FDA says this about it (lightly reformatted by me for ease of reading):

  • The draft guidance was prepared under the auspices of the International Council for Harmonisation (ICH), formerly the International Conference on Harmonisation.
  • The draft guidance clarifies, updates, and extends the earlier E9 Statistical Principles for Clinical Trials in two main areas.
  • Concerning estimands, it provides a framework for discussion of how the aims of a trial relate to the proposed statistical analysis.
  • Concerning sensitivity analysis, it discusses how to use additional analyses to address concerns about the validity of assumptions underlying the main analysis.
  • The draft guidance is intended to better align the choice of statistical methods with questions of regulatory importance and to improve the reliability of decisions about and representations of the effects of medical products.

I’m still digesting this one but at its heart is the problem of including important intercurrent events (e.g., change therapy) in the trial’s outcome measures. The term estimand is introduced as the idea of a measurement that includes the population of interest, the endpoint of interest, a specification of how intercurrent events are handled, and a population level summary of the endpoint.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

Ways to talk about AMR / Video chat with Maryn McKenna

Dear All, Explaining AMR to our colleagues is not easy! I wrote in a 30 Oct 2019 newsletter about what Wellcome Trust learned on this point when they interviewed 12,000 people in Germany, India, Japan, Kenya, the UK, the USA and Thailand — in brief, there are universal themes that improve the likelihood that your message will

G7 Health ministers 3-4 June communique / Implications for choosing wisely

Note: Newsletter now updated to include the communique from the G7 Finance Ministers! Dear All, The G7 met in Oxford this past week and we now have communiques released from by both the Health and Finance Ministers. Let’s look first at the two fascinating statements from the Health Ministers: A general communique that includes multiple

WHO consultancy: Rollout of Policy Guidance on Integrated Stewardship Activities

Dear All, Just below my signature you will find the full details on a recently posted WHO consultancy opportunity. It’s an intriguing 6-month project during which you would be responsible for the rollout and implementation of a new WHO Policy Guidance on the Implementation of Integrated Antimicrobial Stewardship Activities. This guidance will be rolled out in

Scroll to Top